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Highlights 
 New HILIC-HPLC-MS method was developed for determination of TPMT activity 
 HILIC-HPLC-MS combination was approved by excellent performance parameters 
 HILIC-HPLC-MS was compared to traditional RP-HPLC-UV as well as advanced 
RP-HPLC-MS 
 Conventional approaches were surpassed in terms of selectivity, LOD, analysis time 
 HILIC-HPLC-MS is favorable for routine assay of 6-MMP/6-MP ratio in RBC lysates 
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Abstract 
Thiopurine S-methyltransferase (TPMT) plays an important role in the metabolism of 
thiopurines used in the therapy of inflammatory bowel diseases (IBD). In this work a new 
progressive method for the determination of TPMT activity in red blood cells lysates was 
developed. Analysis was carried out by means of hydrophilic interaction liquid 
chromatography (HILIC) hyphenated with mass spectrometry (MS). In comparison with 
reversed-phase high-performance liquid chromatography (RP-HPLC), that has been typically 
applied in determination of TPMT activity, the HILIC significantly improved the analytical 
signal provided by MS, shortened analysis time, and improved chromatographic resolution. 
The HILIC-HPLC-MS method was optimized and validated, providing favorable parameters 
of detection and quantitation limits (5.5 and 16.5 pmol/mL, respectively), linearity 
(coefficient of determination 0.9999 in the range of 0.01-1.0 nmol/mL), recovery and 
precision (93.25-100.37% with RSD 1.06-1.32% in the whole concentration range of QC 
samples). Moreover, in contrast to the conventional RP-HPLC-UV approach, the complex 
phenotype TPMT profiles can be reliably and without interferences monitored using the 
HILIC-HPLC-MS method. Such advanced monitoring can provide valuable detail 
information on the thiopurines (e.g. evaluating ratio of methylated and non-methylated 6-
mercaptopurine) and, by that, TPMT action in biological systems before and during the 
therapy of IBD. 
 
Key words: HILIC-HPLC-Q-TOF MS analysis; inflammatory bowel diseases; red blood cell 
lysates; thiopurine S-methyltransferase activity determination. 
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1. Indroduction 
Thiopurine drugs, namely azathioprine (AZA), 6-mercaptopurine (6-MP) and 6-
thioguanine (6-TG), are immunosuppressive agents that are, due to their low cost and high 
effectiveness, widely used in the treatment of inflammatory bowel diseases (IBD), but also in 
other autoimmune diseases, some hemopoetic disorders and some solid organ transplant [1–
5]. However, the occurrence of adverse drug reactions limits the use of these drugs. Up to 15 
% of IBD patients discontinue this type of treatment due to adverse events that include 
nausea, skin reactions, pancreatitis, hepatotoxicity or myelotoxicity [6,7]. 
 Thiopurine drugs are prodrugs, so their biological activity is preceded by extensive 
metabolism. Briefly, after absorption, AZA is metabolized in the liver to 6-MP which then 
can be metabolized to active thioguanine nucleotides (TGN) and to inactive methylated 
product 6-methylmercaptopurine (6-MMP) by the thiopurine-S-methyl transferase (TPMT) 
enzyme [8]. TPMT (EC 2.1.1.67), a key enzyme involved in the thiopurine drug metabolism, 
is subject to common genetic polymorphism that leads to trimodial distribution of the TPMT 
activity in population [9]. Individuals with lower TPMT activity might have an increased risk 
of developing thiopurine-induced myelosuppression. On the contrary, individuals with high 
TPMT activity have lower concentrations of active TGN metabolites resulting in reduced 
therapeutic efficacy of the drug [10]. In addition, high TPMT activity leads to accumulation 
of the hepatotoxic methylated metabolites [11]. Therefore, some scientific committees advise 
to determine the TPMT activity before the start of thiopurine treatment [12] in order to predict 
myelo- and hepatotoxicity and adjust the dose accordingly.
 
 The evaluation of TPMT activity is based on the determination of the actual enzymatic 
activity in red blood cells (RBC) by measuring amount of 6-MMP or 6-methylthioguanine (6-
MTG) produced by the TPMT-mediated methylation of 6-MP or 6-TG in presence of the 
methyl donor, most commonly S-adenosyl-L-methionine (SAM) [13,14].  
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The very first analytical method used for determination of the methylated products 
produced by TPMT was radiochemical assay published by Weinshilboum et al. [15]. In this 
method S-adenosyl-L-[
14
C] methionine was used as the methyl donor and the products created 
during incubation were detected by liquid scintillation counting. Although this analytical 
approach was preferred for many years it is associated with several disadvantages such as 
work with radioactive material, complexity of analytical protocol, requirements on liquid-
liquid or solid-phase extraction. Moreover, the radiochemical method is more time-consuming 
than currently preferred HPLC methods [16]. Over the years more suitable methods for 
TPMT phenotyping were developed, namely mass spectrometry [14], capillary 
electrophoresis combined with UV detection [17] or, most commonly, HPLC coupled with 
UV/DAD [16,18–27] or fluorescence detection [28]. Although separations with non-selective 
UV detection have been preferred due to their simplicity and low cost, increasing demands on 
the reliability of data and more detail sample profiles stimulated development of more 
advanced methods. In this area, only one method employing HPLC hyphenated with MS 
detection has been published so far [29]. However, this HPLC-MS method was not validated 
and only limited number of data is available thus far. In summary, the methods currently used 
for TPMT phenotyping are relatively time-consuming and/or poorly validated which 
precludes them from wide-spread use in optimizing the treatment with thiopurines. 
 The aim of this work was thus to develop a new method for TPMT phenotype. For this 
purpose, hydrophilic interaction liquid chromatography (HILIC) hyphenated with mass 
spectrometry (MS) was tested as a progressive alternative to the reversed-phase (RP)-HPLC 
methods that have been used for the determination of the TPMT activity so far. In order to see 
progress and effectivity enhancement of the proposed HILIC-HPLC-MS method, it was 
compared with traditional (RP-HPLC-UV) as well as newer (RP-HPLC-MS) approaches 
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through their performance parameters, analysis time, and information value of the recorded 
sample profiles. 
 
2. Materials and methods 
2.1 Chemicals and solutions 
 6-MP, 6-MMP, SAM and 6-chloropurine (Cl-P) were obtained from Sigma-Aldrich 
(Steinheim, Germany). Dithiothreitol (DTT) was obtained from AppliChem GmbH 
(Darmstadt, Germany). Other chemicals were obtained from Fluka Chemie GmbH (Buchs, 
Switzerland). All chemicals used were of analytical grade. All solutions were prepared in 
water demineralized by a Direct-Q 3 UV water purification system (Merck Millipore, 
Molsheim, France).  
Phosphate buffer solution (50 µmol/mL) was prepared by mixing equimolar amounts 
of Na2HPO4 and NaH2PO4 and adjusting the pH to 7.4 with NaOH. The stock solutions of 6-
MP (30 µmol/mL) and 6-MMP (0.1 µmol/mL) were prepared in 100 µmol/mL
 
NaOH. The 
stock solutions of SAM (6 µmol/mL) and DTT (50 µmol/mL) were prepared by dissolving 
the standards in phosphate buffer solution. The stock solution of Cl-P (0.1 µmol/mL), serving 
as an internal standard, was also prepared by dissolution in the phosphate buffer solution. All 
of the stock solutions were kept frozen at - 20 °C until use. 
 
2.2. Procedures for sample and standard solution preparations 
2.2.1 Standard solutions 
 The calibration solutions of 6-MMP were prepared in 100 µmol/mL NaOH and in the 
matrix, which was prepared in same manner as the RBC samples but the addition of 6-MP 
was omitted. The calibration solutions used in the RP-HPLC-DAD, RP-HPLC-MS, and 
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HILIC-HPLC-MS methods were prepared in the concentration ranges of 0.1 – 10.0, 0.1 – 5.0, 
and 0.01 – 1.00 nmol/mL, respectively. Each calibration point was measured in duplicate.  
 The QC samples were prepared by spiking the precipitated RBC lysate (matrix) with 
the stock solution of 6-MMP. The QC samples at three concentration levels (low, medium, 
high, 0.1, 0.5, 1 nmol/mL, respectively) were prepared, and each was measured five times. 
 
2.2.2 Blood sample collection and preparation 
 Blood samples from healthy volunteers were collected in EDTA tubes and 
immediately placed into the fridge at 4 °C where they were stored until further processing. All 
the samples were processed within 24 h of the blood sampling.  
 RBC were separated from the whole blood by the centrifugation at 800 g for 10 min at 
4 °C. After the centrifugation, the plasma, buffy coat and upper layer of RBC were discarded. 
The isolated RBC were washed by the resuspendation in a 0.9 % saline solution followed by 
the centrifugation at 800 g for 5 min at 4 °C, and, finally, by the removal of the saline wash 
solution. The washing step was repeated twice. After the second washing step, the packed and 
washed RBC were diluted with a 0.9 % saline solution (1:1, v/v). Afterwards, the diluted RBC 
were frozen and stored at - 20 °C until incubation and analysis.  
 
2.2.3 Incubation conditions 
 The determination of TPMT activity is based on the reaction of the substrate (6-MP) 
with the methyl donor (SAM) that is catalyzed by the TPMT enzyme and results in the 
methylated product (6-MMP). The reaction mixture (final volume 500 μL) consisted of 325 
μL of phosphate buffer solution, 10 μL of 6-MP stock solution (final concentration 600 
nmol/mL), 10 μL of 0.1 mmol/mL HCl, 10 μL of SAM stock solution (final concentration 120 
nmol/mL), 10 μL of DTT stock solution (serving as inhibitor of oxidation of the thiols; final 
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concentration 1 µmol/mL), and 10 μL of Cl-P stock solution (internal standard). The mixture 
was shaken and the enzymatic reaction was started by the addition of 100 μL of a freshly 
thawed RBC lysate under a 37 °C incubation. After 1 hour the enzymatic reaction was 
stopped by the addition of 25 μL of perchloric acid (60 %) to the reaction mixture which 
resulted in precipitation of the sample. The precipitated sample was centrifuged at 12500 g for 
10 min. The supernatant was filtered through a 0.22 m nylon syringe filter (AZ Chrom, 
Bratislava, Slovakia), and used for the HPLC analysis. In case of the HILIC column, the 
supernatant was diluted 10 times in the initial mobile phase. 
 
2.3 Apparatus 
 All of the analyses were performed on the chromatographic apparatus consisting of LC 
Agilent Infinity System equipped with a gradient pump (1290 Bin Pump VL), an automatic 
injector (1260 HiPals), and column thermostat (1290 TCC), coupled with photodiode array 
detector (Infinity 1290 DAD), and quadrupole time-of-flight mass spectrometer (6520 
Accurate Mass Q-TOF LC/MS) equipped with electrospray ionization source operated in 
positive ionization mode, and a computer with Mass Hunter software (version MassHunter 
Workstation B.05.01) for data acquisition and processing (Agilent Technologies, Santa Clara, 
CA, USA). Parameters of calibration line for 6-MMP were calculated by using Microsoft 
Excel 2007 (Microsoft Corporation, Redmond, WA, USA). The thermostat of the autosampler 
was set at 4 °C. The 6-MMP was evaluated at the wavelength of 280 nm. The following 
parameters were used for the mass spectrometer: drying gas temperature 300 °C, drying gas 
flow 10 L/min., nebulizing gas pressure 40 psi, ESI source voltage 3500 V, fragmentor 
voltage 140 V, collision gas N2. 
 
2.4 Chromatographic conditions for RP column 
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 The separation was performed using a C8 column LiChroCART
®
 125-4 LiChrospher
®
 
100 RP-8 (125 x 4,0 mm, 5 µm) along with a guard column (LiChrospher
®
 100 RP-8, 5 µm, 
4x4 mm), both Merck KGaA (Darmstadt, Germany). The temperature of the column was 
maintained at 35 °C. The mobile phase A consisted of a 10 µmol/mL
 
ammonium formate 
buffer with pH 3.1 (adjusted with formic acid) and mobile phase B consisted of 100 % 
acetonitrile. The flow rate of the mobile phase was set at 0.4 mL/min. The following gradient 
elution was used: initial composition was set at 15 % of B and kept isocratic for 10 minutes, 
after that the composition was raised to 100 % of B during 2 minutes, kept at a 100 % level of 
B for 4 minutes, and then lowered to the initial 15 % of B during 2 minutes. The column was 
reconditioned with the initial composition of the mobile phases for 5 minutes with the flow 
rate of 0.8 mL/min. The injection volume was 10 μL.  
 
2.5 Chromatographic conditions for HILIC column 
 The separation was performed using a HILIC column SeQuant
®
 ZIC
®
-HILIC 3.5 μm, 
2.1 x 100 mm (Merck KGaA) with a guard column Nucleodur HILIC 5μm, 4x2 mm 
(Macherey-Nagel, Duren, Germany). The same temperature, mobile phase constituents, and 
flow rate were used as in case of the RP-column. The following gradient elution was used: 
initial composition was set at 97 % of B and kept isocratic for 2 minutes, after that the 
composition was changed to 10 % of B during 4 minutes, kept at a 10 % level of B for 4 
minutes, and afterwards changed to the initial 97 % of B during 1 minute. The column was 
reconditioned with the initial composition of the mobile phases for 5 minutes with the flow 
rate of 0.4 mL/min. The injection volume was 1 μL. 
 
3. Results and discussion 
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 Three HPLC methods were systematically optimized (optimum parameters are 
summarized in sections 2.3-2.5), validated (validation data are summarized in Tables 1 and 2) 
and compared to each other in order to establish a new highly effective and reliable method 
for the determination of thiopurine S-methyltransferase activity suitable for the routine 
clinical use. A conventional approach is represented by the RP-HPLC-UV method, advanced 
approach by RP-HPLC-MS method, and the new progressive approach by the HILIC-HPLC-
MS method. 
 
3.1 Method development 
 While most of the published methods used a C18 RP-column [18,19,22–29], we 
preferred a C8 RP-column in order to improve separation of 6-MMP from the matrix 
constituents. This is critical when using non-selective UV detection. The retention times of 6-
MMP in the published RP-HPLC methods ranged between ca. 4 and 27 min [22,27] while in 
our case it was 9.3 min. The optimized C8 RP-HPLC-UV method was suitable for the 
identification of 6-MMP as well as 6-MP, however, some partial overlapping could not be 
avoided as it can be seen in Fig. 1. The presence of such interference makes the evaluation of 
the obtained data difficult and can be source of inaccuracies in the results of the assay. 
 Therefore, in the second step, C8 RP-HPLC was hyphenated with MS in order to 
enhance detection selectivity. The optimized chromatographic separation conditions were the 
same as those used in the RP-HPLC-UV method (section 2.4). The use of MS detection 
significantly enhanced orthogonality of the analytical system as MS hyphenation provided 
specific detection based on different m/z values of the analyzed compounds. Therefore, 
interferences of the analytes with compounds originating from the sample matrix, as they 
were seen in RP-HPLC-UV, were prevented when using the RP-HPLC-MS method, see Fig. 
2. On the other hand, the shapes of some peaks were not optimum. For example, a splitting of 
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6-MP peak was observed, probably due to an interaction with the matrix in the ion source (see 
the elution position of 6-MP in the TIC chromatogram, upper panel in Fig. 2). It is necessary 
to mention, however, that poor peak shape of 6-MP (substrate) has no relevance in the 
determination of TPMT activity based on 6-MMP (enzymatic product) quantification. On the 
other hand, we suppose information in varying amount of the original substrate (6-MP) in 
incubated RBC samples could be useful for further investigation of the thiopurine metabolism 
in different biological systems (e.g. different patients). 
 In the third step, the chromatographic conditions were modified to be more favorable 
with respect to the elution parameters of the analytes and ESI-MS compatibility. A method 
employing the HILIC column coupled with the MS detection was developed as an alternative 
to the RP-HPLC-MS. To our best knowledge, this is the first method that uses this type of 
column for the TPMT activity determination. The HILIC column, providing polar interactions 
with the analytes, was responsible for considerable changes in separation selectivity (e.g. 
reversing migration order of 6-MMP and 6-MP). Applying higher concentration of less polar 
organic phase (acetonitrile) in HILIC separation was favorable for the combination with MS, 
so that significantly higher detection responses of the analytes were obtained in comparison 
with the RP-HPLC-MS approach. Moreover, the shapes of the analytes peaks were improved 
as it can be seen in Fig. 3. Very important benefit of the HILIC separation was considerable 
shortening in the 6-MMP retention. By using this column, the obtained retention time of 6-
MMP was 1.28 min that was several times lower value than the lowest value obtained in the 
TPMT activity studies so far, e.g. 4.42 min in ref. [16]. In comparison to our RP-HPLC-
UV/MS methods (described above) the total analysis time, including reconditioning of the 
column, for the HILIC-HPLC-MS method was lower by 7 minutes. 
 
3.2 Evaluation of performance parameters 
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Performance parameters of the optimized RP-HPLC-UV, RP-HPLC-MS, and HILIC-
HPLC-MS methods were evaluated for the 6-MMP standard present in the model (spiked) 
RBC lysate matrix, and the resulting data are given in Table 1. The precise mass of 6-MMP, 
found by the high-resolution Q-TOF MS, was 167.0386 (m/z [M+H]
+
 ± 20 ppm). The 
performance parameters were evaluated according to the ICH guideline [30].  
Linearity, tested in the concentration range up to two decadic orders and expressed via 
coefficient of determination (r
2
), was acceptable for the analyte measured in the RBC lysate 
matrices. This range was suitable also for the concentration levels of 6-MMP monitored 
during the TPMT activity determination.  
The limits of detection (LOD) and quantitation (LOQ) for 6-MMP in the injected 
samples (prepared according to the standard procedure given in sections 2.2.2 and 2.2.3), 
calculated from the calibration lines as 3.3σa/b and 10σa/b, respectively, were in sub µmol/mL 
level when using RP-HPLC-UV/MS methods, while they were ca. 20-times lower when using 
HILIC-HPLC-MS method. This highlighted usefulness of the HILIC-HPLC-MS method in 
the ultra-trace determination of 6-MMP in RBC lysates (and, by that, to determine lower 
TPMT activities) and in the analysis of reduced amounts of the sample (lower consumption of 
biological material). Although LOD/LOQ values presented as nmol/mL demonstrated limits 
of given analytical method in determination of 6-MMP in 1 mL of injected sample, in clinical 
practice these limits are usually presented as nmol/mL RBC including correction (i.e. 
increasing) of these values for given RBC dilution (done during sample preparation 
procedure). The later expression is practical for clinicians as it refers to minimum TPMT 
activity (nmol/mL RBC/h) that can be determined under real sample preparation conditions in 
clinical laboratory. Although LOD/LOQ (nmol/mL RBC) of the HILIC-HPLC-MS method 
can be additionally improved (injecting 10-times less diluted samples), the given value 
reflects practical requirements of the present work (i.e. expected higher TPMT activities in 
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healthy volunteers and, by that, need for additional sample dilution to be analytical signal in 
the linear range of the calibration line). 
Ionization suppression due to coeluting matrix (i.e. matrix effect) was evaluated by 
comparing peak areas obtained after direct injection of the samples into MS and 
corresponding with 6-MMP spiked into the mobile phase and into the RBC lysate matrix, see 
the left panel in Fig. 4. The obtained value (103.09 % in favor of the RBC lysate matrix) 
indicated negligible/low matrix effects when determining 6-MMP in the RBC lysate samples.  
From the data in Table 1 it is apparent that the proposed methods provided excellent 
precision of the analyses, where RSD of migration times and peak areas did not exceed 1.0 
and 2.0%, respectively. The results were comparable and consistent for all the methods tested. 
The findings in this paragraph approved the methods for the practical highly reproducible 
measurements. 
The analysis of the QC samples on the low, medium and high (i.e. 0.1, 0.5, 1 
nmol/mL, respectively) concentrations of the spiked 6-MMP verified the accuracy of the three 
methods in the TPMT activity determination. The average recoveries for expected 
concentration levels of 6-MMP in clinical samples were 92.46, 98.45, and 97.23% in case of 
RP-HPLC-UV, RP-HPLC-MS, and HILIC-HPLC-MS methods, respectively. The HPLC-MS 
methods provided consistent and more accurate results than the HPLC-UV method. Detail 
data obtained from the recovery test using the HILIC-HPLC-MS method are summarized in 
Table 2. Generally, the recovery test approved acceptable accuracy of all the examined 
methods and, by that, their suitability for the practical use in the RBC lysate matrices.  
As expected, the HPLC-MS methods have superior specificity when compared to the 
HPLC-UV method. The influence of the co-eluting peaks originating from the matrix was 
eliminated due to specific MS response towards to the analyte. Therefore, the HPLC-MS 
approach is recommended for highly reliable analyses of 6-MMP in the RBC lysate matrices. 
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Taking into consideration all the performance parameters, the highest criteria were 
fulfilled by the HILIC-HPLC-MS method. This method was superior (in comparison with RP-
HPLC-UV/MS methods) especially in parameters of sensitivity, selectivity, analysis time, and 
sample consumption. Hence, usefulness of this new method for practical routine use in the 
TPMT activity determination was clearly confirmed. 
 
3.3 Method application 
All three of the presented methods have been applied for the determination of TPMT 
activity in the RBC lysates of two healthy volunteers and the results were compared. It was 
found out that the TPMT activity of the first and the second volunteer ranged in the intervals 
of 10.59 – 10.86 nmol/mL RBC/h and 10.62 – 12.18 nmol/mL RBC/h, respectively. These 
values refer to a nmol/mL concentration of enzymatically produced 6-MMP corrected for the 
given RBC dilution (as stated in sections 2.2.2 and 2.2.3). The results obtained from the three 
methods were comparable and consistent that confirmed their good accuracy and usefulness 
for the routine clinical use.  
In addition to the evaluation of matrix effects described in section 3.2, the results 
obtained from the calibration curve were compared with those obtained by the method of 
standard addition where any matrix effects are compensated (eliminated). For the records 
illustrating additions of the 6-MMP standard to a volunteer RBC lysate sample, see the right 
panel in Fig. 4. The differences (relative errors) between the TPMT activity determined in the 
volunteer samples by the calibration curve and by the method of standard addition ranged in 
the interval of -2.18% – 0.46%. These results confirmed negligible/low influence of the 
matrix effects on the determination of TPMT activity in RBC lysates, and, by that, usefulness 
of the proposed method for its practical applications. 
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Anyway, the HILIC-HPLC MS method was suitable not only for the faster and more 
sensitive determination of 6-MMP, but also for the highly reliable monitoring of the original 
substrate (6-MP), as it can be seen in Fig. 5. It can be valuable for the simultaneous 
determination of TPMT activity as well as the level of free 6-MP that serves as a precursor for 
the in-vivo synthesis of the active thioguanine nucleotides. As the levels of free 6-MP can 
differ among patients (see also profiles of two volunteers in Fig. 5), it would be interesting to 
investigate relationship between these levels and real therapeutic profit of thiopurines on 
different patients. In this way, a more complex view on the thiopurine metabolism can be 
easily obtained yet before starting the thiopurine therapy. In order to see benefits of such 
complex analytical information, however, the evaluation of TPMT activity in the large groups 
of patients prior thiopurine treatment will be needed. 
 
4. Conclusion 
 Three HPLC methods, namely RP-HPLC-UV using traditional concept, RP-HPLC-
MS using advanced detection, and HILIC-HPLC-MS using new progressive concept 
combining advanced separation and detection, were developed for the determination of TPMT 
activity in RBC lysates.  
The performance parameters clearly demonstrated that the HILIC-HPLC-MS method 
was superior not only over traditional RP-HPLC-UV method but also over advanced RP-
HPLC-MS method used for the TPMT activity determination. It is well documented 
especially via improved sensitivity (determination of lower TPMT activity), selectivity 
(minimized interferences), shortened analysis time (more analyzed samples in time unit), 
reduced sample consumption (beneficial to patients), i.e. parameters playing key role in 
routine bioanalysis. Therefore, the HILIC-HPLC-MS method is proposed as a new 
progressive method in the routine clinical TPMT activity determination.  
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In addition, the HILIC-HPLC-MS method enables the simultaneous and highly 
reliable determination of TPMT activity as well as the level of free 6-MP that serves as a 
precursor for the in-vivo synthesis of the active thioguanine nucleotides. In this way, a more 
complex view on the thiopurine metabolism can be easily obtained yet before starting the 
thiopurine therapy. This potential for the clinical practice will be evaluated in our next work 
including statistically significant groups of IBD patients.  
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Figure captions 
 
Figure 1: Representative profiles of the incubated RBC sample and the blank matrix obtained 
by the RP-HPLC-DAD method. The blank matrix (blue) was prepared in the same manner as 
the RBC sample (green) but without 6-MP (see sections 2.2.2 and 2.2.3). For the working 
conditions see sections 2.3 and 2.4. SAM – S-adenosyl-L-methionine; 6-MP – 6-
mercaptopurine; 6-MMP – 6-methylmercaptopurine. 
 
Figure 2: Representative profiles of the incubated RBC sample and the blank matrix obtained 
by the RP-HPLC-MS method. Upper panel: TIC chromatograms. The blank matrix (blue) was 
prepared in the same manner as the RBC sample (green) but without 6-MP (see sections 2.2.2 
and 2.2.3). Lower panel: EIC chromatograms extracted according to following m/z [M+H]+ 
of the analytes (± 20 ppm): 167.0386 (6-MMP), 155.0112 (Cl-P), 153.0226 (6-MP), 399.1450 
(SAM). For the working conditions see sections 2.3 and 2.4. 6-MMP – 6-
methylmercaptopurine; 6-MP – 6-mercaptopurine; SAM – S-adenosyl-L-methionine; Cl-P – 
6-chloropurine. 
 
Figure 3: Representative profiles of the incubated RBC sample obtained by the HILIC-
HPLC-MS method. EIC chromatograms extracted according to following m/z [M+H]+ of the 
analytes (± 20 ppm): 167.0386 (6-MMP), 155.0112 (Cl-P), 153.0226 (6-MP), 399.1450 
(SAM). For the sample preparation see sections 2.2.2 and 2.2.3. For the working conditions 
see sections 2.3 and 2.5. 6-MMP – 6-methylmercaptopurine; 6-MP – 6-mercaptopurine; SAM 
– S-adenosyl-L-methionine; Cl-P – 6-chloropurine. 
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Figure 4: EIC profiles used for the evaluation of matrix effects. Left panel: analytical signals 
(peaks) of 6-MMP (1 nmol/mL) spiked into the mobile phase and into the RBC matrix. The 
samples were injected directly into MS (1 l injection volume). Right panel: analytical signals 
(peaks) of 6-MMP spiked in different concentrations into the incubated RBC sample obtained 
from the volunteer 2. The samples were injected into HILIC-HPLC-MS (1 l injection 
volume). EIC chromatograms extracted according to following m/z [M+H]+ of 6-MMP (± 20 
ppm): 167.0386. For the sample preparation see sections 2.2.2 and 2.2.3. For the working 
conditions see sections 2.3 and 2.5. 6-MMP – 6-methylmercaptopurine.  
 
Figure 5: EIC profiles of the incubated RBC samples of two volunteers illustrating advanced 
TPMT determination by the HILIC-HPLC-MS method. EIC chromatograms extracted 
according to following m/z [M+H]+ of the analytes (± 20 ppm): 167.0386 (6-MMP), 
153.0226 (6-MP). For the sample preparation see sections 2.2.2 and 2.2.3. For the working 
conditions see sections 2.3 and 2.5. 6-MMP – 6-methylmercaptopurine; 6-MP – 6-
mercaptopurine.  
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Table 1: Performance parameters of three different HPLC methods for determination of 6-
MMP in spiked RBC lysate matrix
a
 
Parameter RP-HPLC-DAD RP-HPLC-MS HILIC-HPLC-MS 
Linearity range (nmol/mL) 0.1 – 10.0 0.1 – 5.0 0.01 – 1.0 
tR̅(min.), n = 12 9.2605 9.3726 1.2813 
SDtR (min.), n = 12  0.0176 0.0193 0.0049 
RSDtR (%), n = 12  0.1903 0.2057 0.3854 
RSDpeak area (%), n = 6 0.8332 1.1829 0.5458 
Slope (b)  108.5 3468952.6 727274.6 
SDb, n = 12  0.9458 42776.5 2560.0 
Intercept (a)  -2.2933 501412.2 260.6 
SDa, n = 12 4.9114 109075.8 1203.1 
Coefficient of determination (r
2
) 0.9991 0.9988 0.9999 
LOD
b
 (nmol/mL), 3.3σa/b  0.1494 0.1038 0.0055 
LOD
c
 (nmol/mL RBC) 1.4937 1.0376 0.5459 
LOQ
b
 (nmol/mL), 10σa/b 0.4526 0.3144 0.0165 
LOQ
c
 (nmol/mL RBC) 4.5263 3.1443 1.6542 
aFor the standard/sample preparation see section 2.2. For the working conditions see sections 
2.3 (UV, MS), 2.4 (RP-HPLC) and 2.5 (HILIC-HPLC).  
b
LOD and LOQ calculated for 6-MMP in 1 mL of sample 
c
LOD and LOQ calculated for 6-MMP in 1 mL of RBC (corrected for 10- or 100-time 
dilution of RBC lysate matrix when using RP-HPLC-DAD/MS or HILIC-HPLC-MS, 
respectively)  
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Table 2: Accuracy of HILIC-HPLC-MS method for determination of 6-MMP in QC samples
a
 
 Concentration level 
Parameter Low Medium High 
Range (min % – max %) 93.25 – 96.98 97.48 – 100.37 96.39 – 99.31 
Mean (%) 94.75 98.89 98.05 
RSD (%) 1.3237 1.1115 1.0638 
aFor the standard/sample preparation see section 2.2. For the working conditions see sections 
2.3 (MS), and 2.5 (HILIC-HPLC). The RBC lysate matrix was spiked with 6-MMP in three 
concentration levels (low, medium, high, 0.1, 0.5, 1 nmol/mL, respectively), each QC sample 
was measured five times. 
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